Listing of Claims

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A ~~compounds~~ compound of the Formula:



wherein:

R^1 is selected from:

a) hydrogen,

b) aryl, heterocycle, C_3-C_{10} cycloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, and

c) C_1-C_6 alkyl, unsubstituted or substituted with 1 to 5 substituents selected from:

1) aryl, unsubstituted or substituted with 1 to 5 substituents selected from:

i) C_1-C_6 alkyl, unsubstituted or substituted with 1-3 fluoro,

ii) C_3-C_6 cycloalkyl,

iii) C_2-C_6 alkynyl,

iv) OR^{10},

v) aryl,

vi) heterocycle,

vii) CN, and

viii) halo;

2) heterocycle, unsubstituted or substituted with 1 to 5 substituents selected from:

i) C_1-C_6 alkyl, unsubstituted or substituted with 1-3 fluoro,

ii) $-OR^{10}$,

iii) aryl, and

iv) halo;

3) C_3-C_{10} cycloalkyl,

4) C_2-C_6 alkenyl,

5) C_2-C_6 alkynyl,

6) $-OR^{10}$,

7) $-S(O)_mR^{11}$,

8) $-NR^6-C(O)R^7$,

9) $-C(O)-N(R^6)(R^7)$,

10) -CN,

11) $-NR^6-C(O)-N(R^6)(R^7)$,

12) $-C(O)-OR^{10}$,

13) halo, and

14) $-N(R^6)(R^7)$;

R^2 is selected from:

a) $-NR^6-C(O)R^7$,

b) $-NR^6-S(O)_2R^7$, and

~~d)~~ c) ~~$-NR^6-S(O)^2-N(R^6)(R^7)$~~ $-NR^6-S(O)_2-N(R^6)(R^7)$;

R^3 and R^4 are independently selected from:

hydrogen, aryl, heterocycle, halo, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_4 haloalkyl, $R^{10}O$-, $R^{11}S(O)_m$-, $R^6C(O)$-NR^7-, CN, $(R^6)(R^7)N$-C(O)-(NR^6)-, $(R^6)(R^7)$-N-C(O)-, $R^{10}C(O)$-, $R^{10}OC(O)$-, and $N(R^6)(R^7)$; or

wherein R^3 and R^4 are optionally joined to form a saturated or unsaturated ring, containing 0-3 heteroatoms, wherein said ring is phenyl, pyridyl, pyrimidinyl, pyrazinyl, thiophenyl, furanyl, imidazolyl, thiazolyl, oxazolyl, and triazolyl, as well as partially saturated analogues thereof, said ring optionally substituted with one or more of:

aryl, heterocycle, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_2-C_6 alkynyl, $R^{10}O$-, $R^{11}S(O)_m$-, $R^6C(O)N\ R^7$-, ~~$R^6S(O)2NR^7$~~ $-R^6S(O)_2NR^7$-, $(R^6)(R^7)N$-C(O)-, CN, $R^{10}OC(O)$-, F, and $-N(R^6)(R^7)$;

R^6 and R^7 are independently selected from hydrogen, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, heterocycle, aryl, unsubstituted or substituted withone or more of:

a) C_1-C_4 alkyl,
b) C_1-C_4 alkoxy,
c) aryl or heterocycle,
d) halo,
e) $-OR^{10}$, and
f) $-N(R^{10})_2$;

wherein R^6 and R^7 may be joined to form a ring;

R^{10} is independently selected from hydrogen, C_1-C_6 alkyl, $-CF_3$, C_3-C_{10} cycloalkyl, benzyl, and aryl;

R^{11} is independently selected from C_1-C_6 alkyl, and aryl;

m is 0, 1, or 2;

and pharmaceutically acceptable salts and individual diastereomers thereof.

2. (Original) The compound according to Claim 1, wherein R^1 is $-CH_2$-aryl, unsubstituted or substituted with 1-3 substituents selected from: fluoro, chloro, bromo, iodo and methyl.

3. (Original) The compound according to Claim 1, wherein R^1 is benzyl, substituted with 1-3 fluoro.

4. (Original) The compound according to Claim 1, wherein R^1 is $-CH_2C(O)OR^{10}$.

5. (Original) The compound according to Claim 1, wherein R^1 is $-CH_2C(O)OC(CH_3)_3$.

6. (Original) The compound according to Claim 1, wherein R^1 is -$CH_2C(O)NHR^6$.

7. (Original) The compound according to Claim 1, wherein R^1 is -$CH_2C(O)NH(C_4$-C_{10} cycloalkyl).

8. (Original) The compound according to Claim 1, wherein R^1 is -$CH_2C(O)NH$-aryl.

9. (Original) The compound according to Claim 1, wherein R^2 is -NR^6-$S(O)_2R^7$.

10. (Original) The compound according to Claim 1, wherein R^3 is hydrogen.

11. (Original) The compound according to Claim 1, wherein R^3 and R^4 are joined to form a ring selected from: phenyl, pyridyl, pyrimidinyl and pyrazinyl.

12. (Original) The compound according to Claim 1, wherein R^3 and R^4 are joined to form a pyridyl ring.

13. (Original) The compound according to Claim 1, wherein R^4 is bromo.

14. (Original) The compound according to Claim 1, wherein R^4 is -$C(O)OR^{10}$.

15. (Original) A compound selected from:


F
N
S
O
O
N
H
N
Br
F
OH
O

,


O
S
O
N
N
H
N
Br
F
OH
O

,


N
S
O
O
N
H
N
O
CH3
CH3
CH3
O
Br
OH
O

,


N
S
O
O
N
H
N
O
N
H
Br
OH
O

,


S
O
O
N
N
Br
H
N
O
N
H
OH
O

,


S
O
O
N
N
Br
H
N
O
N
H
OH
O

,


S
O
O
N
N
Br
H
N
O
N
H
OH
O

,


S
O
O
N
N
F
H
N
F
N
OH
O

,


S
O
O
N
N
H
N
I
N
OH
O

,


S
O
O
N
N
Cl
H
N
Cl
N
OH
O

,



,



,

and pharmaceutically acceptable salts and individual diastereomers thereof.

16. (Original) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 1.

17. (Canceled)

18. (Currrently Amended) A method for treating, controlling, ameliorating or reducing the risk of headache~~, migraine or cluster headache~~ in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of the compound of Claim 1.

19 24. (Canceled)

25. (New) The method of claim 18, wherein the headache is migraine headache or cluster headache.